Last reviewed · How we verify
LY3303560 - IV
LY3303560 - IV is a Small molecule drug developed by Eli Lilly and Company. It is currently in Phase 1 development.
At a glance
| Generic name | LY3303560 - IV |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD) (PHASE1)
- A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease (PHASE1)
- A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY3303560 - IV CI brief — competitive landscape report
- LY3303560 - IV updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI
Frequently asked questions about LY3303560 - IV
What is LY3303560 - IV?
LY3303560 - IV is a Small molecule drug developed by Eli Lilly and Company.
Who makes LY3303560 - IV?
LY3303560 - IV is developed by Eli Lilly and Company (see full Eli Lilly and Company pipeline at /company/eli-lilly).
What development phase is LY3303560 - IV in?
LY3303560 - IV is in Phase 1.
Related
- Manufacturer: Eli Lilly and Company — full pipeline
- Compare: LY3303560 - IV vs similar drugs
- Pricing: LY3303560 - IV cost, discount & access